PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ambrx Biopharma Inc. (AMAM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02290A1025
CUSIP02290A102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.77B
EPS (TTM)$0.42
PE Ratio66.67
Total Revenue (TTM)$1.18M
Gross Profit (TTM)$1.18M
EBITDA (TTM)-$45.34M
Year Range$6.55 - $28.15
Target Price$28.67
Short %3.28%
Short Ratio1.21

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Ambrx Biopharma Inc.

Popular comparisons: AMAM vs. KAMN, AMAM vs. VTSAX, AMAM vs. PFE, AMAM vs. SMCI, AMAM vs. PLTR

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ambrx Biopharma Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17
64.22%
25.63%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A14.57%
1 monthN/A2.97%
6 monthsN/A14.93%
1 yearN/A24.71%
5 years (annualized)N/A13.14%
10 years (annualized)N/A10.88%

Monthly Returns

The table below presents the monthly returns of AMAM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202495.22%0.50%96.63%
2023-16.74%240.21%38.72%8.02%53.19%11.52%-7.35%-7.41%-18.56%-9.48%10.85%23.40%527.31%
2022-46.40%-7.23%-8.24%-7.52%3.15%-32.57%4.91%-40.65%-34.55%-9.54%-49.85%363.27%-74.86%
202114.96%-0.26%-8.90%-24.20%-6.67%-25.79%-3.42%-47.04%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of AMAM is 94, placing it in the top 6% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of AMAM is 9494
AMAM (Ambrx Biopharma Inc.)
The Sharpe Ratio Rank of AMAM is 9191Sharpe Ratio Rank
The Sortino Ratio Rank of AMAM is 9494Sortino Ratio Rank
The Omega Ratio Rank of AMAM is 9494Omega Ratio Rank
The Calmar Ratio Rank of AMAM is 9797Calmar Ratio Rank
The Martin Ratio Rank of AMAM is 9393Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ambrx Biopharma Inc. (AMAM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AMAM
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.24, compared to the broader market-2.00-1.000.001.002.003.002.24
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.16, compared to the broader market-4.00-2.000.002.004.006.003.16
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.78, compared to the broader market0.002.004.006.001.78
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.36, compared to the broader market0.0010.0020.008.36

Sharpe Ratio

There is not enough data available to calculate the Sharpe ratio for Ambrx Biopharma Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio0.002.004.006.008.0010.00Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17
1.69
2.85
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ambrx Biopharma Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-40.00%-30.00%-20.00%-10.00%0.00%Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17
-0.32%
-0.14%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ambrx Biopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ambrx Biopharma Inc. was 98.18%, occurring on Dec 8, 2022. Recovery took 270 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.18%Jul 14, 2021356Dec 8, 2022270Jan 8, 2024626
-6.45%Jun 21, 20212Jun 22, 20213Jun 25, 20215
-4.08%Jul 1, 20211Jul 1, 20212Jul 6, 20213
-2.47%Jul 9, 20212Jul 12, 20211Jul 13, 20213
-2.27%Jun 28, 20211Jun 28, 20211Jun 29, 20212

Volatility

Volatility Chart

The current Ambrx Biopharma Inc. volatility is 0.89%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10Mar 17
0.89%
2.70%
AMAM (Ambrx Biopharma Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ambrx Biopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items